How Amgen uses GPT-5

Source: OpenAI Date: 2025-08-07 URL: https://openai.com/index/gpt-5-amgen

Summary

Title-only: A GPT-5 case study featuring Amgen, the large-cap biopharmaceutical company. Published on the same day as several other GPT-5 case studies and the GPT-5 system card, this is part of the coordinated GPT-5 enterprise launch narrative. Amgen’s use likely involves drug discovery acceleration, clinical data analysis, research literature synthesis, or regulatory documentation — the high-value pharma workflows where GPT-5’s advanced reasoning and long context would have clearest ROI.

Implications

The life sciences enterprise thread. Amgen joining the GPT-5 launch day case study roster alongside other enterprise partners signals that OpenAI has closed major pharma deals at the GPT-5 tier. Pharma case studies are strategically important because they demonstrate AI value in regulated, high-stakes domains — which translates to credibility for healthcare, legal, and finance verticals.

GPT-5 launch day coordination. The cluster of case studies (Amgen, Wrtn, others) published on 2025-08-07 is deliberate: OpenAI is shipping social proof simultaneously with the model to preempt the “where’s the real enterprise adoption?” critique. This PR strategy mirrors AWS re:Invent customer announcements — the launch day case study is now standard OpenAI product playbook.